Core-Vector Core
$211,669P01FY2008HLNIH
Lsu Health Sciences Center, New Orleans LA
Investigators
Linked publications & trials
Paper 35067963Paper 33632562Paper 31064629Paper 30213614Paper 28860145Paper 28797931Paper 28604843Paper 28444190Paper 28012778Paper 27925857Paper 27823900Paper 27821559Paper 27405853Paper 27242785Paper 27234399Paper 26974294Paper 26864029Paper 26851260Paper 26844553Paper 26823337Paper 26774965Paper 26603633Paper 26500629Paper 26483405Paper 26317509Paper 26169874Paper 25448310Paper 25176030Paper 25173628Paper 24686066Paper 23909594Paper 23451104Paper 23203926Paper 23176655Paper 22349523Paper 22036596Paper 22014229Paper 21357267Paper 21343353Paper 20020829Paper 19558669Paper 19220915Paper 19155505Paper 18798835Paper 18483422Paper 18332204Paper 17933755Paper 17889309Paper 17403873Paper 17362490Paper 17339468Paper 17207109Paper 16308571Paper 16239546Paper 16113296Paper 15803058
Abstract
The Vector Core will provide viral vectors to investigators for each research project in the context of this Program Project Grant. The Vector Core will construct, produce and test adenovirus-based vectors. These vectors will be used to express CXCR3 ligands, IL-17, IL-17R-IgG, mycobacterial and Pneumocystis antigens, and ovalbumin (OVA) in the lungs of experimental animals outlined in Projects 1, 2 and 4. The Vector Core will also construct, produce and test recombinant fowlpox viruses (FPV) expressing mycobacterial antigens, CXCR3 ligands and OVA. Recombinant FPV vectors will be used in prime-boost approaches outlined in Projects 1 to 4.
View original record on NIH RePORTER →